These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 28547968

  • 1. Morphologic evaluation of the effect of denosumab on giant cell tumors of bone and a new grading scheme.
    Erdogan KE, DevecI MA, Paydas S, Gonlusen G.
    Pol J Pathol; 2016; 67(4):392-397. PubMed ID: 28547968
    [Abstract] [Full Text] [Related]

  • 2. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
    Wojcik J, Rosenberg AE, Bredella MA, Choy E, Hornicek FJ, Nielsen GP, Deshpande V.
    Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
    [Abstract] [Full Text] [Related]

  • 3. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls.
    Roitman PD, Jauk F, Farfalli GL, Albergo JI, Aponte-Tinao LA.
    Hum Pathol; 2017 May; 63():89-97. PubMed ID: 28235628
    [Abstract] [Full Text] [Related]

  • 4. Giant Cell Lesions of the Maxillofacial Skeleton Express RANKL by RNA In Situ Hybridization Regardless of Histologic Pattern.
    Stagner AM, Sajed DP, Nielsen GP, Ebb DH, Faquin WC, Chebib I, Rivera MN, Ting DT, Resnick CM, Peacock ZS, Kaban LB, Deshpande V.
    Am J Surg Pathol; 2019 Jun; 43(6):819-826. PubMed ID: 30998511
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The risk of neurological deterioration while using neoadjuvant denosumab on patients with giant cell tumor of the spine presenting with epidural disease: a meta-analysis of the literature.
    Al Farii H, McChesney G, Patel SS, Rhines LD, Lewis VO, Bird JE.
    Spine J; 2024 Jun; 24(6):1056-1064. PubMed ID: 38301904
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Denosumab treatment for progressive skull base giant cell tumor of bone in a 14 year old female - a case report and literature review.
    Bardakhchyan S, Kager L, Danielyan S, Avagyan A, Karamyan N, Vardevanyan H, Mkhitaryan S, Papyan R, Zohrabyan D, Safaryan L, Sargsyan L, Harutyunyan L, Hakobyan L, Iskanyan S, Tamamyan G.
    Ital J Pediatr; 2017 Mar 29; 43(1):32. PubMed ID: 28356124
    [Abstract] [Full Text] [Related]

  • 16. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
    Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S.
    Lancet Oncol; 2010 Mar 29; 11(3):275-80. PubMed ID: 20149736
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone.
    Lau CP, Huang L, Wong KC, Kumta SM.
    Connect Tissue Res; 2013 Mar 29; 54(6):439-49. PubMed ID: 24060052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.